Quark signs on to develop additional molecules against three targets using Silence’s technology.

Silence Therapeutics and Quark Pharmaceuticals reported an expansion of their current strategic technology licensing agreement.

In April 2005 the companies signed an option and license agreement, which provided Quark with access to Silence Therapeutics’ siRNA technology, AtuRNAi.

The expanded agreement provides Quark with options to nonexclusive licenses to develop additional molecules against three specific targets using AtuRNAi. The terms of the amendment will entitle Silence Therapeutics to milestone payments and a royalty on product sales after exercise of the options by Quark.

Previous articleLaureate to Manufacture Enobia Pharma’s Candidate against Hypophosphatasia
Next articlePall to Use Chembio’s Dual Path Platform Immunoassay